Key result
Highly selective beta-1 blockers, such as bisoprolol, provide complete control of sympathetic hyperactivation in arterial hypertension by inhibiting sympathetic activity in the heart and kidneys.
Highly selective beta-1 blockers are highlighted as effective agents for controlling sympathetic overdrive and preventing myocardial remodeling in patients with arterial hypertension.
Answers are grounded in this paper and cite their sources.
Supports selective beta-blocker consideration in hypertension; leaves open confirmation of remodeling prevention in randomized trials.
Hyperactivation of the sympathetic nervous system (sympathetic overdrive) is the central mechanism for the development of arterial hypertension. Among antihypertensive drugs, only beta-blockers without internal sympathetic activity, for example, bisoprolol, provide complete control of sympathetic hyperactivation. Highly selective β1-adrenergic blockers inhibit sympathetic activity in the heart and kidneys, preserving β2-mediated vasodilation and reducing the risk of adverse effects due to β2-receptor blockade in the lungs and peripheral tissues.
No takes yet. Share an insight, caveat, or question.
N. E. Aydargalievа (2020) conducted a review in Arterial hypertension. Highly selective beta-1 blockers (e.g., bisoprolol) was evaluated. Highly selective beta-1 blockers, such as bisoprolol, provide complete control of sympathetic hyperactivation in arterial hypertension by inhibiting sympathetic activity in the heart and kidneys.
Synapse has enriched 10 related papers. Consider them for comparative context: